These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30015837)

  • 1. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
    Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.
    Han M; Gu Y; Lu P; Li J; Cao H; Li X; Qian X; Yu C; Yang Y; Yang X; Han N; Dou D; Hu J; Dong H
    Mol Cancer; 2020 Feb; 19(1):26. PubMed ID: 32020881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
    Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
    Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of Exosomal AGAP2-AS1 (AGAP2 Antisense RNA 1) In Breast Cancer Cells Inhibits Trastuzumab-Induced Cell Cytotoxicity.
    Zheng Z; Chen M; Xing P; Yan X; Xie B
    Med Sci Monit; 2019 Mar; 25():2211-2220. PubMed ID: 30910994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.
    Sun Z; Zhang C; Wang T; Shi P; Tian X; Guo Y
    J Cancer Res Ther; 2019; 15(4):933-940. PubMed ID: 31436255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
    Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
    Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation.
    Dong H; Wang W; Mo S; Liu Q; Chen X; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J; Hu J
    J Cell Mol Med; 2018 Oct; 22(10):4935-4947. PubMed ID: 30063126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.
    Zhang W; Cai X; Yu J; Lu X; Qian Q; Qian W
    Int J Oncol; 2018 Aug; 53(2):527-538. PubMed ID: 29845246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.
    Dong H; Wang W; Mo S; Chen R; Zou K; Han J; Zhang F; Hu J
    J Exp Clin Cancer Res; 2018 Aug; 37(1):202. PubMed ID: 30157918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
    Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
    Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
    Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
    Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA.
    Kang M; Ren M; Li Y; Fu Y; Deng M; Li C
    J Exp Clin Cancer Res; 2018 Jul; 37(1):171. PubMed ID: 30049286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosome-mediated transfer of circHIPK3 promotes trastuzumab chemoresistance in breast cancer.
    Zhang H; Yan C; Wang Y
    J Drug Target; 2021 Nov; 29(9):1004-1015. PubMed ID: 33775192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
    Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
    Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
    Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H
    Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.